The role of mannose binding lectin in infectious complications of paediatric hemato-oncologic diseases

Despite significant changes in pediatric oncological therapy, mortality is still high, mainly due to infections. Complement system as an ancient immune defense against microorganisms plays a significant role in surmounting infections, therefore, deficiency of its components may have particular importance in malignancies. The present paper assesses the effect of promoter (X/Y) and exon 1 (A/0) polymorphisms of the MBL2 gene altering mannose binding lectin (MBL) serum level in pediatric oncological patients with febrile neutropenia. Furthermore, frequency distribution ofMBL2 alleles in children with malignancies and age-matched controls was analysed. Fifty-four oncohematological patients and 53 children who had undergone pediatric surgery were enrolled into this retrospective study. No significant differences were found in the frequency of MBL2 alleles between the hematooncologic and control group. The average duration of fever episodes was significantly shorter (p = 0.035) in patients carrying genotypes (AY/AY and AY/AX) that encode normal MBL level, compared to individuals with genotypes associated with lower functional MBL level (AX/AX, AY/0, AX/0, or 0/0) (days, median (IQ range) 3.7(0–5.4) vs. 5.0(3.8–6.6), respectively). In conclusion, our data suggest that MBL2 genotypes may influence the course of febrile neutropenia in pediatric patients with malignancies, and may contribute to clarification of the importance of MBL in infections.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.14232/phd.10884
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The High Prevalence of Functional Complement Defects Induced by Chemotherapy

  2016cited by this paper
• The role of mannose binding lectin on fever episodes in pediatric oncology patients

  2015cited by this paper
• Complement in health and disease.

  2015cited by this paper
• MBL-associated serine proteases (MASPs) and infectious diseases

  2015cited by this paper
• New insights into the role of ficolins in the lectin pathway of innate immunity.

  2015cited by this paper
• Mannose binding lectin and ficolin‐2 polymorphisms are associated with increased risk for bacterial infections in children with B acute lymphoblastic leukemia

  2014cited by this paper
• The Lectin Pathway of Complement and Rheumatic Heart Disease

  2014cited by this paper
• Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBL-substitution therapy.

  2014cited by this paper
• Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria

  2013cited by this paper
• First of Two Parts

  2013cited by this paper
• Mannose-binding Lectin Genotype Influences Frequency and Duration of Infectious Complications in Children With Malignancy

  2013cited by this paper
• Mannose-Binding Lectin 2 Polymorphisms Do Not Influence Frequency or Type of Infection in Adults with Chemotherapy Induced Neutropaenia

  2012cited by this paper
• Association between serum levels of MASP-2 and neutropenic febrile attacks in children with leukemia.

  2012cited by this paper
• Serum Levels of Mannose-Binding Lectin and the Risk of Infection in Pediatric Oncology Patients With Chemotherapy

  2012cited by this paper
• Infections in hematological malignancies.

  2012cited by this paper
• Collectin-11/MASP Complex Formation Triggers Activation of the Lectin Complement Pathway - The Fifth Lectin Pathway Initiation Complex

  2012cited by this paper
• Human L-Ficolin (Ficolin-2) and Its Clinical Significance

  2012cited by this paper
• Mannose‐binding lectin (MBL) and the risk for febrile neutropenia and infection in pediatric oncology patients with chemotherapy

  2011cited by this paper
• Complement deficiency states and associated infections.

  2011cited by this paper
• The role of ficolins in the lectin pathway of innate immunity.

  2011cited by this paper
• Mannose‐binding lectin (MBL) as prognostic factor in paediatric oncology patients

  2011cited by this paper
• Complement and its role in innate and adaptive immune responses

  2010cited by this paper
• Collectin 11 (CL-11, CL-K1) Is a MASP-1/3–Associated Plasma Collectin with Microbial-Binding Activity

  2010cited by this paper
• Prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose‐binding lectin‐associated serine protease‐2 (MASP‐2)

  2009cited by this paper
• Mannan-binding lectin-associated serine protease-2 (MASP-2) in a large cohort of neonates and its clinical associations.

  2009cited by this paper
• Disease associations of mannose-binding lectin & potential of replacement therapy.

  2008cited by this paper
• Mannose-binding lectin genetics: from A to Z.

  2008cited by this paper
• Mannose-binding Lectin MBL2 Gene Polymorphisms and Outcome of Hepatitis C Virus-infected Patients

  2008cited by this paper
• Baseline mannose binding lectin levels may not predict infection among children with leukemia

  2008cited by this paper
• The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia

  2008cited by this paper
• Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy.

  2007cited by this paper
• Deficiency of Mannose-Binding Lectin-Associated Serine Protease-2 Associated With Increased Risk of Fever and Neutropenia in Pediatric Cancer Patients

  2007cited by this paper
• Serum levels of mannose‐binding lectin and the risk of fever in neutropenia pediatric cancer patients

  2007cited by this paper
• A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.

  2007cited by this paper
• Infections during induction therapy of childhood acute lymphoblastic leukemia – no association to mannose‐binding lectin deficiency

  2006cited by this paper
• Phase I Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Mannan-Binding Lectin

  2006cited by this paper
• Mannose-binding lectin and its genetic variants

  2006cited by this paper
• Mannose-binding lectin and upper respiratory tract infections in children and adolescents: a review.

  2006cited by this paper
• Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity.

  2006cited by this paper
• Mannose‐binding lectin in innate immunity: past, present and future

  2006cited by this paper
• M‐ficolin, an Innate Immune Defence Molecule, Binds Patterns of Acetyl Groups and Activates Complement

  2005cited by this paper
• Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT

  2005cited by this paper
• Differential substrate and inhibitor profiles for human MASP-1 and MASP-2.

  2004cited by this paper
• The hypothalamic–pituitary–adrenal axis in critical illness: responses to the low-dose corticotropin (ACTH) stimulation test and human corticotropin-releasing hormone (hCRH)

  2004cited by this paper
• Human Plasma‐Derived Mannose‐Binding Lectin: A Phase I Safety and Pharmacokinetic Study

  2004cited by this paper
• The Second of Two Parts

  2003cited by this paper
• Mannose-binding lectin deficiency--revisited.

  2003cited by this paper
• Recombinant mannan-binding lectin (MBL) for therapy.

  2003cited by this paper
• Role of the mannose-binding lectin in innate immunity.

  2003cited by this paper
• Clinical potential of mannose-binding lectin-replacement therapy.

  2003cited by this paper
• Activation of the Lectin Complement Pathway by H-Ficolin (Hakata Antigen)1

  2002cited by this paper
• The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes.

  2002cited by this paper
• Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia.

  2002cited by this paper
• Complement. Second of two parts.

  2001cited by this paper
• Complement. First of two parts.

  2001cited by this paper
• Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma – a rationale for tailored supportive care

  2001cited by this paper
• Association between deficiency of mannose-binding lectin and severe infections after chemotherapy.

  2001cited by this paper
• Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study.

  2001cited by this paper
• Mannose-Binding Lectin Binds to a Range of Clinically Relevant Microorganisms and Promotes Complement Deposition

  2000cited by this paper
• Epidemiology of childhood cancer.

  1999cited by this paper
• Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia.

  1999cited by this paper
• Association of low levels of mannan-binding protein with a common defect of opsonisation.

  1989cited by this paper

• No citing papers are available for this paper.